|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
WO1996033735A1
(en)
|
1995-04-27 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DK0585287T3
(da)
|
1990-07-10 |
2000-04-17 |
Cambridge Antibody Tech |
Fremgangsmåde til fremstilling af specifikke bindingsparelementer
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
CA2131151A1
(en)
|
1992-03-24 |
1994-09-30 |
Kevin S. Johnson |
Methods for producing members of specific binding pairs
|
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
|
JPH08509612A
(ja)
|
1993-04-26 |
1996-10-15 |
ジェンファーム インターナショナル インコーポレイテッド |
異種抗体を産生することができるトランスジェニック非ヒト動物
|
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
|
FR2707189B1
(fr)
|
1993-07-09 |
1995-10-13 |
Gradient Ass |
Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
|
|
WO1995015388A1
(en)
|
1993-12-03 |
1995-06-08 |
Medical Research Council |
Recombinant binding proteins and peptides
|
|
DE69535243T2
(de)
|
1994-07-13 |
2007-05-10 |
Chugai Seiyaku K.K. |
Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1332209B1
(en)
|
2000-09-08 |
2009-11-11 |
Universität Zürich |
Collections of repeat proteins comprising repeat modules
|
|
EP2141243A3
(en)
|
2000-10-16 |
2010-01-27 |
Brystol-Myers Squibb Company |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
|
KR100953520B1
(ko)
|
2001-06-22 |
2010-04-21 |
츄가이 세이야꾸 가부시키가이샤 |
항글리피칸 3항체를 포함하는 항암제
|
|
WO2003029462A1
(en)
|
2001-09-27 |
2003-04-10 |
Pieris Proteolab Ag |
Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
|
|
AU2003234775A1
(en)
|
2002-04-30 |
2003-11-17 |
Dnavec Research Inc. |
Vector with modified protease-dependent tropism
|
|
US7750204B2
(en)
|
2002-06-05 |
2010-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing antibody
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
WO2004022595A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
MRL/lprマウスを用いた抗体の作製
|
|
US20050164301A1
(en)
|
2003-10-24 |
2005-07-28 |
Avidia Research Institute |
LDL receptor class A and EGF domain monomers and multimers
|
|
JP2005168328A
(ja)
|
2003-12-08 |
2005-06-30 |
Hokkaido Univ |
シグナル伝達活性を有する細胞質蛋白質の活性制御方法
|
|
PL1691837T3
(pl)
|
2003-12-10 |
2012-11-30 |
Squibb & Sons Llc |
IP-10 przeciwciała i ich zastosowanie
|
|
JP5629423B2
(ja)
|
2004-04-12 |
2014-11-19 |
カタリスト バイオサイエンシーズ， インコーポレイテッド |
野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
|
|
SI1674111T1
(sl)
|
2004-07-09 |
2011-02-28 |
Chugai Pharmaceutical Co Ltd |
Protitelo proti glipikanu 3
|
|
MY157915A
(en)
|
2004-12-21 |
2016-08-15 |
Centocor Inc |
Anti-il-12 antibodies, epitopes, compositions, methods and uses.
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
AU2006284651C1
(en)
|
2005-08-31 |
2013-09-12 |
The Regents Of The University Of California |
Cellular libraries of peptide sequences (CLiPS) and methods of using the same
|
|
JP2009519011A
(ja)
|
2005-12-01 |
2009-05-14 |
ドマンティス リミテッド |
インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
|
|
EA200801166A1
(ru)
|
2005-12-01 |
2008-12-30 |
Домантис Лимитед |
Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
|
|
SG175602A1
(en)
|
2006-07-05 |
2011-11-28 |
Catalyst Biosciences Inc |
Protease screening methods and proteases identified thereby
|
|
CA2659574C
(en)
|
2006-08-02 |
2017-04-25 |
The Uab Research Foundation |
Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
|
|
WO2008020079A1
(en)
|
2006-08-18 |
2008-02-21 |
Ablynx N.V. |
Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
|
|
CA2678626A1
(en)
|
2007-02-28 |
2008-09-04 |
Novimmune S.A. |
Anti-ip-10 antibodies and methods of use thereof
|
|
CA2688433A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
|
AU2016213702C1
(en)
|
2007-08-22 |
2018-11-29 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
|
NZ595461A
(en)
|
2009-04-10 |
2013-01-25 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
|
JP2011026294A
(ja)
|
2009-06-26 |
2011-02-10 |
Canon Inc |
化合物
|
|
JP5764127B2
(ja)
|
2009-08-17 |
2015-08-12 |
ロシュ グリクアート アーゲー |
標的化イムノコンジュゲート
|
|
EP2553101A4
(en)
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
PROTEASE-ACTIVATED CYTOKINES
|
|
US9193791B2
(en)
|
2010-08-03 |
2015-11-24 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects
|
|
CN103068847B
(zh)
|
2010-08-24 |
2019-05-07 |
罗切格利卡特公司 |
可活化的双特异性抗体
|
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
|
CN103561771B
(zh)
|
2011-03-17 |
2019-01-04 |
伯明翰大学 |
重新定向的免疫治疗
|
|
WO2012158818A2
(en)
*
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
US9975962B2
(en)
|
2012-03-30 |
2018-05-22 |
Bayer Healthcare Llc |
Thrombin/plasmin-regulated antibodies that bind TFPI
|
|
MX357540B
(es)
|
2012-04-06 |
2018-07-13 |
Omeros Corp |
Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
|
|
EP2852617B1
(en)
|
2012-05-22 |
2018-12-12 |
Life Technologies AS |
Recombinant antibody compositions and methods of use thereof
|
|
EP2863948B1
(en)
|
2012-06-22 |
2018-10-24 |
Cytomx Therapeutics Inc. |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
WO2014125955A1
(ja)
|
2013-02-15 |
2014-08-21 |
国立大学法人京都工芸繊維大学 |
抗体のリフォールディング方法、リフォールディングされた抗体の製造方法、リフォールディングされた抗体、及びこれらの利用
|
|
NZ718283A
(en)
|
2013-09-25 |
2022-05-27 |
Cytomx Therapeutics Inc |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
US9562073B2
(en)
|
2014-01-31 |
2017-02-07 |
Cytomx Therapeutics, Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
WO2015117930A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukine 10 immunoconjugates
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
GB201413357D0
(en)
|
2014-07-28 |
2014-09-10 |
Philogen Spa |
Antibodies for treatment and diagnosis
|
|
MX2017003847A
(es)
|
2014-09-25 |
2017-12-15 |
Amgen Inc |
Proteinas biespecificas activables por proteasas.
|
|
MX2017006016A
(es)
|
2014-11-11 |
2017-06-19 |
Amunix Operating Inc |
Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
IL292798A
(en)
|
2015-05-04 |
2022-07-01 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
|
|
CA2984892A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
EP3296395B2
(en)
|
2015-05-13 |
2024-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
|
|
WO2017025698A1
(en)
|
2015-08-11 |
2017-02-16 |
Queen Mary University Of London |
Bispecific, cleavable antibodies
|
|
WO2017162587A1
(en)
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
MY200695A
(en)
|
2016-11-03 |
2024-01-11 |
Bristol Myers Squibb Co |
Activatable anti-ctla-4 antibodies and uses thereof
|
|
JP7626577B2
(ja)
|
2016-11-28 |
2025-02-07 |
中外製薬株式会社 |
リガンド結合活性が調整可能なリガンド結合分子
|
|
BR112019008727A2
(pt)
|
2016-11-28 |
2019-07-16 |
Chugai Seiyaku Kabushiki Kaisha |
domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
|
|
RU2754058C2
(ru)
|
2016-12-13 |
2021-08-26 |
Астеллас Фарма Инк. |
Антитело к cd73 человека
|
|
JP7249961B2
(ja)
|
2017-06-02 |
2023-03-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
|
|
NZ759601A
(en)
|
2017-06-02 |
2023-06-30 |
Merck Patent Gmbh |
Aggrecan binding immunoglobulins
|
|
JP2020530280A
(ja)
|
2017-07-03 |
2020-10-22 |
トルク セラピューティクス， インコーポレイテッド |
免疫刺激性融合分子およびその使用
|
|
US20190038935A1
(en)
|
2017-08-07 |
2019-02-07 |
Timofey Ignatyev |
Exercise game and apparatus employing color-changing base locations
|
|
CN107602706B
(zh)
|
2017-10-16 |
2020-12-04 |
湖北大学 |
一种切割效率增强的hrv 3c蛋白酶底物突变体及其应用
|
|
JP7482630B2
(ja)
|
2017-11-28 |
2024-05-14 |
中外製薬株式会社 |
抗原結合ドメインおよび運搬部分を含むポリペプチド
|
|
TWI880235B
(zh)
|
2017-11-28 |
2025-04-11 |
日商中外製藥股份有限公司 |
可調整配體結合活性的配體結合分子
|
|
KR102020131B1
(ko)
|
2017-12-29 |
2019-09-09 |
박성원 |
광경화성 조성물 및 이를 이용하여 제조된 성형품
|
|
EP3762406A2
(en)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Cytokine prodrugs
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
US20210253672A1
(en)
|
2018-05-30 |
2021-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule containing single domain antibody
|
|
JP7428661B2
(ja)
|
2018-05-30 |
2024-02-06 |
中外製薬株式会社 |
Ｉｌ－１ｒ１結合ドメインおよび運搬部分を含むポリペプチド
|
|
JP7414736B2
(ja)
|
2018-05-30 |
2024-01-16 |
中外製薬株式会社 |
アグリカン結合ドメインおよび運搬部分を含むポリペプチド
|
|
US20210355219A1
(en)
|
2018-09-21 |
2021-11-18 |
Harpoon Therapeutics, Inc. |
Conditionally activated target-binding molecules
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
CN114127277A
(zh)
|
2019-06-05 |
2022-03-01 |
中外制药株式会社 |
蛋白酶底物和包含蛋白酶切割序列的多肽
|
|
WO2020246563A1
(ja)
|
2019-06-05 |
2020-12-10 |
中外製薬株式会社 |
抗体切断部位結合分子
|
|
BR112022001320A2
(pt)
|
2019-07-25 |
2022-04-12 |
Univ Chicago |
Composições e métodos compreendendo agentes terapêuticos ativados por protease
|
|
EP4093875A4
(en)
|
2020-01-20 |
2024-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding fusion proteins
|
|
CN117957258A
(zh)
|
2021-07-19 |
2024-04-30 |
中外制药株式会社 |
利用融合多肽的蛋白酶介导的靶向特异性细胞因子递送
|